ADVANCE 01 • Cardiometabolic
SGLT2 inhibitors beyond diabetes
Cardiorenal therapy has expanded from glucose lowering to heart-failure and chronic-kidney-disease protection, including many patients without diabetes.
FREE SAMPLERead Advance →🚀 Newer Advances in Medicine
50 high-yield advances selected for physicians: newer therapeutics, biologics, precision medicine, gene/RNA therapy, advanced diagnostics, devices and clinically important emerging concepts. Each topic emphasizes what changed, mechanism, indications, evidence, bedside relevance and limitations.
✓ TOPICS 1–2 FREE🔒 TOPICS 3–50 MEMBERS
ADVANCE 02 • Cardiometabolic
GLP-1 receptor agonists in obesity and cardiovascular risk
Incretin-based therapy now treats obesity as a chronic biologic disease and can reduce cardiovascular events in selected high-risk patients.
FREE SAMPLERead Advance →ADVANCE 03 • Cardiometabolic
Dual GIP/GLP-1 receptor agonism
Dual incretin agonism can produce larger glucose and weight effects than traditional single-pathway incretin therapy.
🔒 MEMBERSLogin / Register to Open →ADVANCE 04 • Cardiology
ARNI and modern four-pillar HFrEF therapy
HFrEF treatment has shifted from sequential add-on therapy to early use of four disease-modifying drug classes.
🔒 MEMBERSLogin / Register to Open →ADVANCE 05 • Cardiology
Finerenone and non-steroidal mineralocorticoid receptor antagonism
Selective non-steroidal MRA therapy targets inflammatory and fibrotic cardiorenal injury with less endocrine off-target activity than older steroidal agents.
🔒 MEMBERSLogin / Register to Open →ADVANCE 06 • Cardiology
Factor XI/XIa inhibition — the next anticoagulation frontier
Factor XI inhibition aims to separate prevention of pathologic thrombosis from the haemostasis required to stop everyday bleeding.
🔒 MEMBERSLogin / Register to Open →ADVANCE 07 • Cardiology
Transcatheter aortic valve replacement expansion
TAVR has moved from inoperable/high-risk patients into broader surgical-risk groups, with lifetime valve strategy becoming central.
🔒 MEMBERSLogin / Register to Open →ADVANCE 08 • Cardiology
Transcatheter edge-to-edge repair for mitral/tricuspid regurgitation
Catheter-based leaflet repair has created a treatment pathway for selected patients with severe regurgitation who remain symptomatic despite optimized medical care.
🔒 MEMBERSLogin / Register to Open →ADVANCE 09 • Lipidology
PCSK9-targeted therapy: antibodies and siRNA
Very low LDL-C is now achievable through protein inhibition or long-acting RNA silencing of PCSK9.
🔒 MEMBERSLogin / Register to Open →ADVANCE 10 • Hypertension
Renal denervation for resistant hypertension
Device-based sympathetic modulation has re-emerged with sham-controlled evidence showing modest but consistent BP lowering in selected patients.
🔒 MEMBERSLogin / Register to Open →ADVANCE 11 • Nephrology
Endothelin pathway therapy in proteinuric kidney disease
Targeted endothelin blockade is becoming relevant in selected glomerular diseases where persistent proteinuria drives progression.
🔒 MEMBERSLogin / Register to Open →ADVANCE 12 • Nephrology
Complement-targeted therapy in IgA nephropathy
IgA nephropathy is shifting from nonspecific immunosuppression toward pathway-directed therapy.
🔒 MEMBERSLogin / Register to Open →ADVANCE 13 • Nephrology
HIF-prolyl hydroxylase inhibitors for renal anaemia
Oral HIF stabilizers provide an alternative way to stimulate erythropoiesis in CKD by mimicking cellular hypoxia signalling.
🔒 MEMBERSLogin / Register to Open →ADVANCE 14 • Diabetes
Automated insulin delivery and hybrid closed-loop systems
Diabetes technology increasingly automates basal insulin and correction dosing using continuous glucose data.
🔒 MEMBERSLogin / Register to Open →ADVANCE 15 • Diabetes
Continuous glucose monitoring beyond type 1 diabetes
CGM has expanded into type 2 diabetes and can reveal glycaemic patterns that HbA1c alone cannot show.
🔒 MEMBERSLogin / Register to Open →ADVANCE 16 • Endocrinology
Teplizumab and delay of type 1 diabetes
Immune therapy can now delay progression from presymptomatic stage 2 type 1 diabetes to clinical disease in selected high-risk individuals.
🔒 MEMBERSLogin / Register to Open →ADVANCE 17 • Endocrinology
New non-insulin therapies in type 1 diabetes research
Adjunctive and disease-modifying strategies are being studied to reduce insulin burden and preserve beta-cell function.
🔒 MEMBERSLogin / Register to Open →ADVANCE 18 • Obesity
Next-generation incretin combinations and triple agonists
The obesity pipeline is moving beyond single and dual incretins toward multi-receptor agonism and combination pharmacology.
🔒 MEMBERSLogin / Register to Open →ADVANCE 19 • Pulmonology
Biologics for severe asthma
Severe asthma is increasingly treated by endotype rather than escalating nonspecific corticosteroids indefinitely.
🔒 MEMBERSLogin / Register to Open →ADVANCE 20 • Pulmonology
Biologic therapy in COPD
A subset of COPD with type-2 inflammation is becoming a biologically targeted disease rather than a purely bronchodilator-based condition.
🔒 MEMBERSLogin / Register to Open →ADVANCE 21 • Pulmonology
Antifibrotic therapy beyond idiopathic pulmonary fibrosis
The progressive pulmonary fibrosis concept recognizes a common fibrotic behavior across several ILDs.
🔒 MEMBERSLogin / Register to Open →ADVANCE 22 • Pulmonology
Long-acting monoclonal antibodies for respiratory virus prevention
Passive immunization is extending protection against respiratory viruses in high-risk populations.
🔒 MEMBERSLogin / Register to Open →ADVANCE 23 • Infectious Disease
Long-acting HIV treatment and prevention
HIV care is moving beyond daily oral tablets toward long-acting injectable treatment and extended-interval prevention.
🔒 MEMBERSLogin / Register to Open →ADVANCE 24 • Infectious Disease
Novel agents for multidrug-resistant tuberculosis
Shorter all-oral regimens and new antimycobacterial classes have transformed resistant-TB management.
🔒 MEMBERSLogin / Register to Open →ADVANCE 25 • Infectious Disease
New antimicrobial approaches to resistant Gram-negative infection
Treatment increasingly depends on resistance mechanism rather than simply the organism name.
🔒 MEMBERSLogin / Register to Open →ADVANCE 26 • Infectious Disease
Rapid syndromic molecular diagnostics and metagenomics
Diagnosis is moving from culture-only workflows toward rapid multiplex and sequence-based pathogen detection.
🔒 MEMBERSLogin / Register to Open →ADVANCE 27 • Gastroenterology
Vonoprazan and potassium-competitive acid blockade
P-CABs provide rapid, potent and more sustained acid suppression than conventional proton-pump activation-dependent therapy.
🔒 MEMBERSLogin / Register to Open →ADVANCE 28 • Gastroenterology
Endoscopic sleeve gastroplasty and metabolic endoscopy
Endoscopy now offers weight-loss interventions between pharmacotherapy and bariatric surgery.
🔒 MEMBERSLogin / Register to Open →ADVANCE 29 • Hepatology
Resmetirom and targeted therapy for MASH
Metabolic steatohepatitis has entered an era of approved disease-directed pharmacotherapy in selected patients with fibrosis.
🔒 MEMBERSLogin / Register to Open →ADVANCE 30 • Hepatology
RNA interference therapies for metabolic liver disease
RNA therapeutics can silence hepatic production of specific pathogenic proteins with infrequent dosing.
🔒 MEMBERSLogin / Register to Open →ADVANCE 31 • Neurology
Anti-amyloid monoclonal antibodies in early Alzheimer disease
Alzheimer treatment now includes disease-modifying antibodies that remove aggregated amyloid in carefully selected early disease.
🔒 MEMBERSLogin / Register to Open →ADVANCE 32 • Neurology
Gene-silencing therapy in transthyretin amyloidosis
TTR amyloidosis can be treated upstream by reducing production of the pathogenic precursor protein.
🔒 MEMBERSLogin / Register to Open →ADVANCE 33 • Neurology
CRISPR-based in-vivo editing for transthyretin amyloidosis
Single-administration gene editing is being tested to permanently reduce hepatic TTR production.
🔒 MEMBERSLogin / Register to Open →ADVANCE 34 • Neurology
CGRP-targeted migraine prevention
Migraine prevention now directly targets a neuropeptide central to trigeminovascular pain signalling.
🔒 MEMBERSLogin / Register to Open →ADVANCE 35 • Neurology
Disease-modifying therapy in spinal muscular atrophy
SMA is now treatable at the RNA, gene-replacement and splicing levels, with greatest benefit when therapy begins early.
🔒 MEMBERSLogin / Register to Open →ADVANCE 36 • Neurology
BTK inhibitors and next-generation multiple sclerosis therapy
Bruton tyrosine kinase inhibition aims to modulate B cells and CNS-resident myeloid cells with an oral small molecule.
🔒 MEMBERSLogin / Register to Open →ADVANCE 37 • Hematology
Gene therapy for sickle cell disease
Autologous gene therapy can potentially provide a one-time functional cure for selected severe sickle cell disease.
🔒 MEMBERSLogin / Register to Open →ADVANCE 38 • Hematology
Gene therapy for transfusion-dependent beta-thalassemia
Gene addition/editing can restore effective erythropoiesis and eliminate chronic transfusion dependence in many selected patients.
🔒 MEMBERSLogin / Register to Open →ADVANCE 39 • Hematology
Bispecific antibodies in hematologic malignancy
Off-the-shelf bispecific antibodies redirect the patient’s T cells toward tumor antigens without individualized cell manufacturing.
🔒 MEMBERSLogin / Register to Open →ADVANCE 40 • Hematology/Oncology
CAR-T cell therapy: expanding indications
CAR-T has evolved from a last-line leukemia/lymphoma therapy into earlier lines and multiple myeloma, with next-generation constructs under study.
🔒 MEMBERSLogin / Register to Open →ADVANCE 41 • Oncology
Immune checkpoint inhibitors and biomarker-driven immunotherapy
Checkpoint blockade has become foundational across many cancers, but benefit depends on tumor biology and immune context.
🔒 MEMBERSLogin / Register to Open →ADVANCE 42 • Oncology
Antibody-drug conjugates
ADCs combine tumor targeting with delivery of highly potent cytotoxic payloads and are rapidly expanding across oncology.
🔒 MEMBERSLogin / Register to Open →ADVANCE 43 • Oncology
Liquid biopsy and circulating tumor DNA
ctDNA is moving cancer monitoring from imaging/biopsy alone toward minimally invasive molecular surveillance.
🔒 MEMBERSLogin / Register to Open →ADVANCE 44 • Rheumatology
JAK inhibitors in immune-mediated disease
Oral JAK inhibition offers rapid intracellular cytokine modulation across rheumatoid arthritis, inflammatory bowel disease, dermatologic and other immune disorders.
🔒 MEMBERSLogin / Register to Open →ADVANCE 45 • Rheumatology
Targeted complement inhibition in autoimmune disease
Complement blockade has expanded from rare hematologic disease into neurologic and renal autoimmune conditions.
🔒 MEMBERSLogin / Register to Open →ADVANCE 46 • Rheumatology
FcRn inhibitors in autoantibody-mediated disease
FcRn blockade lowers pathogenic IgG without broadly suppressing every immune pathway.
🔒 MEMBERSLogin / Register to Open →ADVANCE 47 • Allergy/Immunology
Upstream alarmin blockade
Targeting epithelial alarm cytokines can suppress multiple downstream inflammatory pathways rather than one terminal cytokine.
🔒 MEMBERSLogin / Register to Open →ADVANCE 48 • Critical Care
AI-assisted sepsis and deterioration prediction
Machine learning can integrate high-frequency EHR data to flag deterioration earlier, but an alert is not a diagnosis.
🔒 MEMBERSLogin / Register to Open →ADVANCE 49 • Critical Care
Awake prone positioning and noninvasive respiratory support
Experience from acute hypoxemic respiratory failure accelerated use of HFNO and awake proning as monitored strategies before intubation.
🔒 MEMBERSLogin / Register to Open →ADVANCE 50 • Critical Care
Personalized hemodynamic assessment with point-of-care ultrasound
POCUS is shifting shock assessment from static labels toward repeated bedside physiology.
🔒 MEMBERSLogin / Register to Open →Educational update module: “Newer” is time-sensitive. Regulatory approvals and guideline positions differ by country and can change. Content is for professional learning and must not replace current prescribing information, local protocols or specialist assessment.